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The Runt box domain DNA‑binding transcription factors (RUNX) play key roles in
hematopoietic, bone, and gastric development. These factors regulate angiogenesis
and tumorigenic events, functioning as either activators or repressors of target genes.
Although RUNX2 is an essential bone maturation factor, it has also been found to promote
transformation in vivo and cell proliferation in vitro, perhaps by associating with specific
coactivators or corepressors. Adenoviral‑mediated overexpression of dominant negative
RUNX2 or specific reduction of RUNX2 with RNA‑interference inhibits cell proliferation.
To determine whether RUNX2 also plays a role in cell transformation, RUNX2 interactions
with the coactivator Yes‑associated protein (YAP65) were examined. RUNX2 associated
with YAP65 via a proline‑rich segment in the C‑terminal domain (PPPY) and coexpression
of RUNX2 and YAP65 significantly increased foci formation and anchorage‑independent
growth relative to each factor alone. However, in contrast to wild‑type RUNX2, a mutant
RUNX2(P409A), which does not bind YAP65, did not cooperate with YAP65 to promote
anchorage‑independent growth. RUNX2 is a strong repressor of the cyclin‑dependent
kinase inhibitor p21CIP1, which is known to mediate cell transformation. Overexpression
of YAP65 prevented RUNX2‑dependent downregulation of p21CIP1 protein expression
while promoting cell transformation. The RUNX2(P409A) mutant retained the ability
to bind DNA and repress the p21CIP1 promoter as shown by DNA precipitation and
luciferase‑reporter assays, respectively, but was not able to relieve repression of the
p21CIP1 promoter. Therefore, these results reveal a novel function of the RUNX2 and
YAP65 interaction in oncogenic transformation that may be mediated by modulation of
p21CIP1 protein expression.
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The RUNX family of transcription factors is composed of three homologous genes
(RUNX1, RUNX2, and RUNX3) each containing a conserved Runt DNA binding
domain. The RUNX proteins are critical for regulation of mammalian developmental
events related to hematopoiesis (RUNX1),1 osteogenesis (RUNX2)2 or epithelial cell
maturation (RUNX3).3 Although RUNX1 has been implicated in certain human
leukemias due to translocation events and mutations, and silencing of the RUNX3
promoter is a causal event in gastric carcinomas, the role of RUNX2 in tumorigenesis
is less characterized. The Runx2 gene is a common target for retroviral insertion and
overexpression resulting in T‑cell lymphomas.4 Overexpression of the RUNX2 gene has
been linked to T‑cell oncogenesis since RUNX2 transgenic mice developed lymphomas
in combination with c‑myc or Pim1, or in the absence of p53.4‑6 Recently, Runx2 was
shown to collaborate with MYC in lymphoma development by suppressing apoptotic
pathways.7 Normal human mammary epithelial cells express low levels of endogenous
RUNX2. However, elevated RUNX2 in malignant breast cancers was found to activate
expression of bone sialoprotein8 and to mediate the formation of osteolytic lesions in bone
metastases.9 Since bone sialoprotein has been associated clinically with skeletal metastasis
and breast cancer cells preferentially metastasize to the bone,10 RUNX2 may play an
important role in breast cancer tumorigenesis. RUNX2 mRNA and protein were also
elevated in high‑grade human melanomas,11 prostate cancer specimens,12 and in the
bone metastatic PC‑3 prostate cell line.13 Induction of RUNX2 and RUNX2‑regulated
gene expression in metastatic prostate tumor cells suggests that activation of osteomimetic
properties may confer a survival advantage in the bone microenvironment.14
RUNX2 is a strong transcriptional activator or repressor of target genes depending
on the recruitment of associating proteins. Corepressors such as mSin3a, histone
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Plasmids. pCMV‑tag2a (NEO) was purchased from Stratagene.
The full length RUNX2 cDNA was inserted into the BamH1/Xho1
sites of the pCMV‑tag2a as previously described.31 Flag‑tag RUNX2
or flag‑tag RUNX2DN (dominant negative; missing exon8) was
subcloned into the pShuttle vector (Clontech) before restriction
enzyme cloning into the Adeno‑X adenoviral vector (BD Biosciences,
Palo Alto, CA). The dominant negative activity of RUNX2DN
was previously quantified using p21CIP1 promoter‑luciferase
assays.31 Adenoviruses were prepared in HEK293 packaging cells by
sequential transfection/infection and viral titers of HEK293
supernatants were determined by cell lysis as recommended by the
manufacturer (BD Biosciences). The YAP65 expression vector and
the empty vector control (XJ540‑HA) were gifts from Dr. Iain
Farrance (University of Maryland, Baltimore, MD). The p21CIP1
promoter luciferase plasmid (WWP‑LUC) was a gift from Dr. Bert
Vogelstein (Johns Hopkins University, Baltimore, MD). Using a
site‑directed mutanagesis kit (Invitrogen), a point mutation was
introduced into the RUNX2 cDNA, which changed the proline at
position 409 to an alanine, to create the RUNX2(P409A) mutant.
The mutation was verified by sequencing.
Immunoprecipitation and western blot analysis. Nuclear
proteins were isolated using NucBuster (Novagen). Protein concentration was determined with the Bio‑Rad Protein Assay. One mg of
protein was diluted into 500 ml of immunoprecipitation (IP)
buffer [20 mM Tris, pH 7.5, 2 mM CaCl2, 1% Triton X‑100 and
1X protease inhibitor cocktail (Roche)] and was precleared with 30 ml
of protein G sepharose. For immunoprecipitations, 1 mg of
antibody (M2 or HA) pre-bound to 30 ml of Protein G sepharose
was combined with Protein G precleared nuclear extracts and
incubated on an orbital shaker for at least 12 hr at 4˚C. The mixture
was centrifuged, and the pellet was washed three times with the
IP buffer. All excess fluid was removed and 2.5 ml reducing agent
(Invitrogen) and 22.5 ml of 4x Laemmli buffer were added to
the pellet. Samples were boiled for 10 min and centrifuged. The
supernatant was loaded on a 4–12% Nu‑PAGE gel (Invitrogen),
and electrotransferred to PVDF membranes (Invitrogen). The
blots were incubated with either anti‑M2 antibody (1:1000) or
anti‑HA antibody (1:5000) followed by horseradish peroxidase‑
conjugated goat anti‑mouse IgG (KPL, Gaithersburg, MD). All
other antibodies were used at concentrations recommended by the
manufacturer (Santa Cruz, Inc., Santa Cruz, CA). Specific proteins
were detected by enhanced chemiluminescence (ECL, Amersham
Pharmcia Biotech, Buckinghamshire, England).
DNA precipitation assays. Two single stranded, biotin
labeled oligonucleotides corresponding to RUNX binding site
A in the distal p21CIP1 promoter were hybridized to generate a
double‑stranded probe. For the wild‑type probe (Runx2 binding site
in bold), the specific oligonucleotides used were 5'GCTCAGTAC
CACAAAAATTC‑biotin 3' (sense) and 5'GAATTTTTGTGGTA
CTGAGC‑biotin 3' (antisense). For the mutant probe, the specific
oligonucleotides used were 5'GCTCAGTCGAACAAAAATTC‑
biotin 3' (sense) and 5'GAATTTTTGTTCGACTGAGC‑biotin
3' (antisense). Equal concentrations of sense oligo and antisense
oligo were added in annealing buffer for a final concentration of
3.33 mM of double-stranded oligo in 0.1 M Tris, pH 7.6, 0.01 M
MgCl2, 0.0034 M DTT. The mixture was heated to 95˚C for
10 min, allowed to cool slowly to 65˚C, then allowed to cool to room
temperature. One mg of nuclear protein was diluted into 500 ml of
DNAP buffer (10 mM Hepes, pH 7.0, 100 mM KCl, 5 mM MgCl2,
10% glycerol, 1 mM DTT, 0.5% NP40, and 1X protease inhibitor
cocktail), and samples were precleared with 30 ml streptavidin-agarose
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deacetylases, and the TLE1/Groucho factor, do not bind DNA,
but are RUNX2‑associating proteins that inhibit transactivation.15‑17 Coactivator proteins such as p300/CBP and CBFb also
do not bind to DNA, but associate with RUNX2 to mediate transactivation.18‑22 One such coactivator, the Yes‑associated protein,
YAP65, is a phosphoprotein that interacts with the proto‑oncogene
c‑yes, a nonreceptor tyrosine kinase of the Src family. YAP65
contains two SH3 domains, a PDZ domain, and a WW domain,23
all of which mediate specific protein interactions. The WW domain
of YAP65 consists of three anti‑parallel b strands forming a
hydrophobic pocket that binds proline containing motifs such as
the peptide ligand motif PPxY.24,25 It has been determined that
the WW domain of YAP65 binds the sequence PPPY in RUNX126
and RUNX2,27 and may interact with RUNX3 because of identical
PPPY motifs in these RUNX family members. Upon phosphorylation, YAP65 is sequestered in the cytoplasm by 14‑3‑3. However,
when YAP65 is unphosphorylated, it is localized to the nucleus
where it can interact with transcription factors. YAP65 is known to
be a strong coactivator of the TEAD/TEF family of transcription
factors28 and p73.29,30 However, the functional significance of the
RUNX‑YAP65 interaction has not been elucidated.
We showed previously that ectopic expression of RUNX2
prevents TGFb‑mediated inhibition of cell growth.31 RUNX2
DNA‑binding activity, cell cycle progression, pRb phosphorylation,
and DNA synthesis correlated with cell proliferation. RUNX2 also
repressed p21CIP1 promoter activity and reduced p21CIP1 protein
levels. RUNX2 modulation of p21Cip1 expression and promotion
of EC proliferation suggested that RUNX2 might promote cellular
transformation. Recently, we reported that shRNA‑mediated
downregulation of RUNX2 inhibited cell proliferation and that
RUNX2 overexpression increased 3T3 fibroblast growth in soft agar,
a transforming activity mediated, in part, through cdk1‑dependent
phosphorylation of RUNX2.32 Further, adenoviral‑mediated overexpression of a dominant negative factor, which inhibits endogenous
RUNX2, inhibited EC proliferation. We now identify the transcriptional coactivator, YAP65, as a synergistic factor that cooperates
with RUNX2 to increase cell transformation. RUNX2 promoted
transcriptional repression of the cdk inhibitor p21CIP1, while YAP65
alleviated this repression at the promoter level through a direct
interaction with RUNX2. Further, we show that, although RUNX2
reduced p21CIP1 protein levels, the addition of YAP65 prevented this
downregulation. Taken together these data suggest that RUNX2 and
YAP65 increase oncogenic transformation by direct protein:protein
interaction and reveal, for the first time, that p21CIP1 regulation is
one possible mechanism for this transforming activity.

Materials and Methods
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Cell culture and reagents. Human bone marrow endothelial cells
(HBME), HEK293, 293T, and NIH3T3 fibroblasts were cultured
in DMEM (Biofluids) and 10% FBS (Biofluids) and used until
passage 20. Stable NIH3T3 cell lines were selected in 1 mg/ml
G418 (Invitrogen) and only used for three more passages after selection. HCT116.p21‑/‑  and parental cells were cultured in McCoy’s
medium containing 10% FBS. Monoclonal anti‑flag M2 antibody
(Sigma) was used to detect or immunoprecipitate the flag‑tagged
RUNX2 or RUNX2(P409A) mutant proteins. Monoclonal
HA.11 antibody (Covance) was used to detect or immunoprecipitate the HA‑tagged YAP65. Anti‑p21CIP1, anti‑cdk4, anti‑PCNA
and anti‑actin antibodies were obtained from Santa Cruz, Inc.
(Santa Cruz, CA). Anti‑RUNX2 antibody (AML3 Ab) was from
Oncogene Research Products (Cambridge, MA).
www.landesbioscience.com
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a Zeiss microscope, and video camera, and images were processed
with Oncor Image software. Each photo contains multiple computer
images fitted together to give a larger representative view of the
colonies in each well. For measurement of foci formation, NIH3T3
cells and transfectants were cultured in 100 mm dishes and allowed
to reach confluence. Cells growing above the fibroblast monolayer
were photographed 25 days after culturing.
Statistical analysis. Results were analyzed using Microsoft Excel
spreadsheets and are expressed as mean values ± SD from at least three
determinations. Significance was calculated using paired analysis
(Excel Office Suite) and expressed as p values.
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RUNX2 promotes cell proliferation. We showed previously that
RUNX2 protein expression and DNA-binding activity correlated
with EC proliferation.31,33 Human bone marrow EC (HBME)
expressed RUNX2 when subconfluent (proliferating), but not at
confluence (growth arrested). We further showed that overexpression of RUNX2 in bovine aortic EC (BAEC), stimulated cell
proliferation, DNA synthesis and pRb phosphorylation,31 while a
dominant negative (DN) RUNX2 variant (with a deletion of exon8)
inhibited cell proliferation. To further define the role of RUNX2 in
EC proliferation, HBME cells were infected with adenoviral vectors
encoding DN or wild-type RUNX2 for 1–4 days. RUNX2 expression was confirmed on day 2 after infection (Fig. 1). Uninfected cells
were used as controls during the 4-day period. RUNX2 increased
HBME proliferation relative to controls by 2.8-fold (day 1), 2.5-fold
(day 2) and 1.8-fold (day 4), while proliferation in cells expressing
DN RUNX2 was inhibited by 50% on day 4 (Fig. 1). In similar
experiments, HBME cells were also infected with adenoviral vector
encoding a control green fluorescent protein (GFP). The growth
rates of control (GFP) infected cells were essentially the same as
the growth rates of uninfected cells (data not shown). Since HBME
express RUNX2, inhibition of proliferation by DN RUNX2 suggests
that endogenous RUNX2 promotes EC proliferation. These data are
consistent with the observation that targeted knockdown of RUNX2
by specific RNA interference inhibited EC proliferation and cell
cycle progression.32
Specific association of RUNX2 and YAP65. RUNX2 oncogenic
activity depends on the interaction of cooperating oncogenes.5 It has
been reported that RUNX2 interacts with YAP65, a c-yes associating
coactivator and putative proto-oncogene. Yeast two-hybrid screening
showed that the WW domain of YAP65 binds to the PPxY motif
(PPPYP) of RUNX126 and RUNX2.27 To verify a direct interaction
between RUNX2 and YAP65, Flag.RUNX2 and HA.YAP65 were
expressed in 293T cells. Lysates were separated into cytoplasmic (C)
and nuclear (N) fractions (Fig. 2A). Ectopic RUNX2 was localized
to the nucleus, while YAP65 was observed in both cytoplasmic and
nuclear fractions. Immunoprecipitation (IP) assays were performed
with nuclear lysates using either a Flag.Tag or HA.Tag antibody and
the proteins were detected by immunoblotting (Fig. 2A). The IP
with Flag.Tag antibody or the reciprocal IP with HA.Tag antibody
identified Flag.RUNX2 and YAP65 in the complexes. Negative
controls (beads alone or nonspecific IgG coupled to beads) did not
reveal either RUNX2 or YAP65 in the immunoprecipitated fractions.
The immunodepleted lysates were analyzed for possible unbound
Flag.RUNX2 or HA.YAP65 by Western blotting. Neither protein
could be detected in the immunodepleted nuclear lysates (data not
shown). If YAP65 was directly interacting with RUNX2 via the PPxY
motif, a mutation of the first proline to an alanine in RUNX2 would

ON

Figure 1. RUNX2 regulates cell proliferation. Human bone marrow EC
(HBME) were infected with adenoviral vectors expressing RUNX2 or
dominant negative RUNX2 (RUNX2DN). After infection (days 1–4), cells were
photographed and cell number (cells/field) was quantified. Nuclear
proteins from HBME cells were prepared after viral infection and the
expression of RUNX2 or RUNX2DN on day two was confirmed by Western
blot using anti-Flag RUNX2 antibody (inset). Results are mean ± SEM of
triplicate samples and are representative of three separate experiments.
*At four days, p ≤ 0.006 for RUNX2 relative to control; **p ≤ 0.003 for
RUNX2DN versus control.
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beads (Pierce). The biotinylated, double stranded DNA probe
(10 ml of a 3.33 mM stock) and 10 mg of poly dI/dC were added to
the supernatant and incubated at 4˚C overnight. To the mixture,
30 ml of the streptavidin beads were added and the incubation
continued at 4˚C for at least 1 hr. The supernatants were then
removed and the beads were washed three times with 0.5 ml of the
DNA precipitation buffer. Laemmli buffer plus reducing agent were
added to the beads and the mixture was boiled for 10 min. After
centrifugation at 14,000 rpm for 2 min, the supernatant was loaded
on a 4–12% NuPage gel to resolve proteins bound to the DNA.
Luciferase assays. Nontransformed, early passage NIH3T3 cells
were plated in 6-well plates at a density of 105 cells per well. Cells
were allowed to recover for 24 hr and then transfected with the
indicated combination of plasmids. For all luciferase assays, the
WWP-LUC plasmid was used at a concentration of 1 mg per well
and the pTK-renilla was used at a concentration of 50 ng per well.
Cells were incubated at 37˚C in a 5% CO2 incubator for 48 hr.
The cells were lysed with 1X passive lysis buffer (Promega). Lysates
were analyzed using the Dual Luciferase Kit (Promega) and a Turner
Design TD 20/20 dual-wavelength luminometer.
Cell proliferation, soft agar assays and foci formation. HBME
or 3T3 fibroblasts were transfected with the Mirus LT1 transfection reagent (Mirus Corporation) as described previously.31 HBME
cells were infected with dilutions of HEK293 viral supernatants
corresponding to equivalent viral titers for 24 hours and harvested
and replated in 24-well plates for proliferation assays. Cells were
photographed after 1, 2, 3 and 4 days and cell numbers in each
representative field were counted. For growth in soft agar, DMEM,
10% FBS, and agar (0.5%) mixture (2 ml) were added and allowed
to cool and solidify at 25˚C for at least 30 min. Cells (20,000) in
0.5 ml DMEM, 10% FBS, and agar (0.33%) were carefully overlaid
on the solidified agar base in each well. This mixture was allowed
to solidify at 25˚C for 30 min. The plates were then incubated for
ten days in a 37˚C, 5% CO2. Colony formation was compared and
photos of representative regions from each well were taken using
858
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reduce YAP65 binding. Therefore, the ability of the RUNX2(P409A)
mutant to interact with YAP65 was assessed (Fig. 2B). Co-IP assays
with the Flag.RUNX2 or Flag.RUNX2(P409A) and HA.YAP65
showed that YAP65 could associate with wild-type RUNX2 but not
with either of two mutant RUNX2 clones (Fig. 2B).
RUNX2 and YAP65 synergistically increase oncogenic
transformation. We showed recently that RUNX2 promotes
cell growth in soft agar.32 To define the biological significance
of the RUNX2/YAP65 interaction, NIH3T3 cells were transfected with RUNX2 or RUNX2 and YAP65 and the appropriate
control vectors. Expression of RUNX2 or YAP65 was verified
with antibodies specific for the Flag or HA-tag
(Fig. 3A). Examination of post-confluent
cultures of transfected NIH3T3 cells revealed
that RUNX2 or RUNX2 + YAP65-transfected
cells grew on top of the confluent cell
monolayers forming cell foci, indicative of
transformation (Fig. 3B). Freshly transfected
cells were prepared and suspended in soft agar
to measure anchorage-independent growth,
another indicator of transformation (Fig. 3C).

.

Figure 2. RUNX2 and mutant RUNX2(P409A) association with YAP65. (A) 293T
cells were cotransfected with Flag-Tag RUNX2 and HA-Tag YAP65. Western blot
analysis was performed on the cytoplasmic, C; and nuclear lysates, N. RUNX2
localizes to the nucleus, while YAP65 is detected in the cytoplasmic and nuclear
extracts (left panel). Nuclear lysate from the cotransfected 293T cells was either
immunoprecipitated with the Flag-specific antibody (RUNX2) or the HA-specific
antibody (YAP65) coupled to protein A-Sepharose beads. Beads alone or beads
coupled to isotype-matched IgG were used as negative controls. Western blot
analysis was performed with the immunoprecipitated proteins (right panel).
(B) Schematic of wild-type RUNX2 and mutant RUNX2(P409A) proteins
(RHD, Runt Homology Domain; NLS; Nuclear Localization Sequence; NMTS,
Nuclear Matrix Targeting Sequence). 293T cells were cotransfected with flagtagged RUNX2 (lane 1), RUNX2(P409A), clone 2 (lane 2), or RUNX2(P409A),
clone 6 (lane 3) and HA-tagged YAP65. Input proteins are shown on the left panel.
Nuclear lysates were immunoprecipitated with the HA-tag antibody coupled to
protein A-Sepharose beads (right panel). Western blot analysis was performed with
either Flag.RUNX2 or HA.YAP65-specific antibodies.
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Figure 3. RUNX2 and YAP65 cooperate to promote
NIH3T3 cell transformation. (A) Western blot of NIH3T3
cells transfected with an increasing amount of RUNX2
or YAP65 (0 mg, 1 mg, 2.5 mg, 5 mg, 10 mg). (B) NIH3T3
cells were transfected with control vectors (NEO and/
or HA), vectors expressing RUNX2 or YAP65, or a
combination of RUNX2 and YAP65 (2.5 mg each).
Foci growing above the fibroblast monolayers were
photographed after 25 days. RUNX2 or RUNX2
and YAP65 transfected cells continued to grow
and form foci atop the monolayers. (C) Parental
NIH3T3 cells transfected with control vectors (NEO
+ HA) or vectors expressing RUNX2, RUNX2 and
YAP65, or the mutant RUNX2(P409A) and YAP65
were cultured in soft agar and photographed after
14 days. (D) The number of colonies from the
NIH3T3 cells growing in soft agar was counted.
Colony number for each treatment was the average
of quadruplicate wells and included five fields per
well (n = 20). *p ≤ 0.004 for YAP65 + NEO vs. HA
control; **p ≤ 0.0007 for RUNX2 + YAP65 vs. HA
control; ***p ≤ 0.002 for RUNX2(P409A) + YAP65
vs. NEO + YAP65.

www.landesbioscience.com
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Figure 4. YAP65-mediated regulation of p21CIP1 cdk inhibitor expression.
(A) HCT116 (p21-/-) or parental cells were harvested and cultured in soft
agar as described in Figure 3. Representative fields from triplicate wells
were photographed and the number of colonies per well was calculated.
Inset shows Western blot confirming reduction of p21Cip1 protein in HCT116
(p21-/-) cells. (B) Expression of p21CIP1, cdk4, PCNA and actin was
measured by Western blot with specific antibodies in cells infected with
increasing doses of RUNX2-expressing adenovirus as described in the
Experimental Procedures. Cells had been previously transfected with control
plasmid or YAP65 (1 mg/well). Western blots were scanned and density of
bands was measured with Adobe Photoshop 7.0 to calculate the p21CIP1:
actin ratios.
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Requirement for p21CIP protein expression in anchorage
independent tumor growth. It was shown that p21CIP1 expression
is permissive for cellular transformation.34 We found previously that
RUNX2 could inhibit expression of p21CIP1 protein in HBME cells
in response to the DNA-damaging agent (and p53 activator) doxorubicin.31 To determine whether p21CIP1 expression was involved
in the ability of RUNX2 and YAP65 to increase cell transformation, we first determined whether p21CIP1 expression could mediate
anchorage-independent growth in an HCT116 tumor cell line from
which the p21CIP1 gene had been deleted.35 Parental and p21CIP1mutant HCT116 cells were cultured in suspension in soft agar. After
two weeks, p21CIP1-negative cells (p21-/-) formed few colonies in
soft agar (Fig. 4A). However, parental HCT116 cells, which express
p21CIP1 protein, formed 6-fold more colonies in soft agar, indicating
that p21CIP1 is essential for anchorage-independent growth. HCT116
p21CIP1-mutant and parental cells exhibited identical growth rates in
culture (data not shown), as reported previously.35 Therefore, the
difference in growth in soft agar may be due to the ability of p21CIP1
to promote anchorage-independent growth and/or cell survival,
which are well-known properties of transformed cells.
To determine whether regulation of p21CIP1 protein expression by
RUNX2 and YAP65 was also permissive for oncogenic transformation, control HBME cells or HBME cells overexpressing YAP65 were
infected with increasing amounts of adenovirus encoding RUNX2.
Confluent cells were harvested and nuclear fractions were analyzed
for p21CIP1 protein by Western blotting (Fig. 4B). As expected,
RUNX2 inhibited p21CIP1 protein expression in a dose-dependent
manner. However, RUNX2 did not repress p21CIP1 protein in
YAP65 overexpressing cells, consistent with the enhanced ability of
YAP65 to promote cell transformation (Fig. 3). From quantitative
densitometry, the p21CIP1/Actin ratios declined with increasing
RUNX2 expression, but were unchanged in the presence of YAP65.
The Western blots were stripped and reprobed for cell cycle and
proliferation-regulatory proteins (Fig. 4B). The levels of the cell cycle
kinase cdk4 or proliferating cell nuclear antigen, PCNA, were not
altered by RUNX2 or YAP65 overexpression.
Repression of the p21CIP promoter in response to RUNX2 and
YAP65. To determine whether YAP65 prevents RUNX2 repression of p21CIP1 expression at the transcriptional level by inhibiting
repression of the p21CIP1 promoter, we first determined whether the
RUNX2(P409A) mutant that does not interact with YAP65 would
retain its ability to bind DNA. A 20 nucleotide synthetic oligonucleotide was created containing the consensus RUNX binding sequence
(RBS) and the flanking sequences from the distal site A in the p21CIP1
promoter (Fig. 5A, a).15,16,31 DNA precipitation assays showed that
RUNX2 was able to bind the wild type p21CIP1 oligonucleotide but
not the mutant oligonucleotide in which the RBS had been altered
(Fig. 5A, b). We expected that the RUNX2(P409A) mutant would
retain its ability to bind DNA since the P409A mutation was downstream of the Runt DNA binding domain (amino acids 50–177). To
measure RUNX2(P409A) DNA binding, nuclear lysates from 293T
cells transfected with either of two mutant Flag.RUNX2(P409A)
clones were isolated. Both RUNX2(P409A) mutant clones retained
DNA-binding activity (Fig. 5A, c).
Ectopic expression of RUNX2 is known to repress p21CIP1
promoter activity in nontransformed NIH3T3 cells.31 Consistent
with published results,16 Flag.RUNX2 repressed a p21CIP1 promoterluciferase construct in NIH3T3 cells (Fig. 5B). NIH3T3 cells
were also transfected with two different clones of the mutant
RUNX2(P409A) and luciferase activity was measured. Both
mutant RUNX2 clones repressed p21CIP1 promoter activity to the
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After two weeks in soft agar, the RUNX2 transfected cells formed
five times more colonies than the NEO (vector alone) controls
(Fig. 3D). Moreover, the colonies formed by the combination of
RUNX2 and YAP65 were two to five-fold larger than those of
RUNX2 expressing cells. The number of colonies formed in the
presence of RUNX2+YAP65 was greater than the number of colonies
expected from expression of RUNX2 or YAP65 separately, indicative
of a synergistic increase in oncogenic transformation. Previous
mutational analysis of the YAP65 binding site of RUNX1 showed
that the first two Pro and the Tyr residues in the YAP65 binding
domain (PPYP) were necessary for transcriptional activation of a
tk-promoter containing a GAL4 binding site.26 Mutation of the first
proline to an alanine completely abolished transcriptional activity.
To determine whether the increased cellular transformation was
mediated by the YAP65 binding site on RUNX2, cells transfected
with a RUNX2(P409A) vector in which the YAP65 binding site had
been mutated (Fig. 2B) were used in the soft agar assay (Fig. 3C).
The RUNX2(P409A) mutant was incapable of increasing cellular
transformation in the absence of YAP65 and even inhibited growth
in soft agar below the levels of the NEO control in the presence of
YAP65 (Fig. 3C and D). These results suggest that a direct interaction between RUNX2 and YAP65 is necessary to induce loss of
contact inhibition and growth in soft agar, established indicators of
cellular transformation.
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Figure 5. Modulation of RUNX2-mediated repression of the p21CIP1 promoter by YAP65. (A) Location of RUNX2
binding sites in the p21CIP1 promoter (sites A–C) in relation to the p53/p73 binding sites (a). The sequences of the
wild type and mutant p21CIP1 double-stranded, biotinylated DNA probes are shown (b). DNA precipitation and
Western blot analyses (b, lanes 1,2 no nuclear lysates) show the ability of RUNX2 to bind the double stranded
oligonucleotide containing the RUNX consensus binding site (b, lane 3). However, RUNX2 is not able to bind
the mutant binding sequence (b, lane 4). (c) 293T cells were transfected with Flag-Tag RUNX2(P409A), clone 2
(lane 1) or RUNX2(P409A), clone 6 (lane 2). Nuclear lysates from the transfectants were incubated with DNA oligos
containing a RUNX2 binding site and streptavidin beads were used to precipitate the bound complexes. Western
blot analysis was performed with the DNA-precipitated proteins. Both mutant RUNX2 clones maintained the ability
to bind the p21CIP1 oligonucleotide (lanes 1A, 2A) with no detectable mutant RUNX2 remaining in the superna‑
tant after precipitation (lanes 1B, 2B). (B) NIH3T3 cells were transfected with pTK-renilla (0.05 mg), WWP-LUC
(1.0 mg), and 1.0 mg of control NEO vector (NEO), RUNX2 (R2), or two different clones of RUNX2(P409A),
clone 2 (cl2) or clone 6 (cl6). Both RUNX2(P409A) clones repressed p21CIP-promoter luciferase activity.
*p ≤ 0.002 for P409A_cl2 vs NEO or for RUNX2 vs NEO; ** p ≤ 0.003 for P409A_cl6 vs NEO. (C) NIH3T3
cells were transfected with pTK-renilla, WWP-LUC, a constant amount of RUNX2, NEO control, or P409A clone
2 DNA (0.25 mg), and increasing amounts of YAP65 (0 mg, 0.1 mg, 0.25 mg, 0.5 mg, 1.0 mg). YAP65 alleviated
the RUNX2 repression of the p21CIP1 promoter. Results represent a combination of data from three separate experi‑
ments performed in duplicate or triplicate (n = 8). *p ≤ 0.004 for RUNX2 vs. NEO control at 0ug YAP65. YAP65
was unable to relieve the RUNX2(P409A) repression of the p21CIP1 promoter. **p ≤ 0.004 for RUNX2(P409A)
vs NEO control at 1.0 mg YAP65. Results represent a combination of data from three separate experiments per‑
formed in triplicate (n = 9).
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same extent as wild type RUNX2
(Fig. 5B). Since YAP65 associates
with RUNX2, we wanted to assess
whether YAP65 could regulate
repression of the p21CIP1 promoter
by RUNX2. At a constant input
(0.25 ug) of NEO control or Flag.
RUNX2 vector, increasing amounts
of HA.YAP65 were added to each
sample (Fig. 5C). HA.YAP65 in
the presence of NEO control had
no significant effect on p21CIP1
promoter activity (Fig. 5C, gray
bars). Increasing concentrations of
HA.YAP65 alleviated the RUNX2
repression of p21CIP1 promoter
activity in a dose dependent
manner, resulting in complete relief
of p21CIP1 promoter repression
at 1.0 ug DNA (Fig. 5C, dark
bars), consistent with the observed
expression of p21CIP1 protein
(Fig. 4B). However, HA.YAP65 was
unable to relieve p21CIP1 promoter
repression by the mutant Flag.
RUNX2(P409A) (Fig. 5C, white
bars). A YAP65 control vector had
no effect on RUNX2 repression
and did not alleviate repression of
the p21CIP1 promoter by RUNX2
or RUNX2(P409A) (data not
shown). Since YAP65 relieved
the RUNX2-mediated, but not
RUNX2(P409A)-mediated repression of the p21CIP1 promoter, these
data suggest that direct YAP65
binding to RUNX2 is necessary to
relieve RUNX2 repression of the
p21CIP1 promoter.
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Tumor progression is characterized by dysregulation of normal
cellular growth controls. Our
studies were designed to determine
the biological consequences of the
interaction of RUNX2 with the
transcriptional coactivator YAP65
in the context of anchorageindependent growth and cellular transformation. YAP65 interacts
with RUNX2 through the PPPY domain of RUNX2. We show for the
first time that one physiological consequence of the RUNX2-YAP65
interaction is to increase cell transformation since NIH3T3 cells
overexpressing RUNX2 and YAP65 exhibited a synergistic increase
in growth in soft agar. Although RUNX2 is a strong transcriptional
repressor of the p21CIP1 promoter, the presence of YAP65 relieved
this repression at both the promoter and protein levels. Further, the
ability of YAP65 to relieve p21CIP1 repression depended on a direct
RUNX2-YAP65 interaction since mutation of the PPPY YAP65binding site on RUNX2 resulted in failure of YAP65 to relieve
www.landesbioscience.com

RUNX2 repression of the p21CIP1 promoter. These data suggest
that the RUNX2 DNA-binding factor may regulate repression or
activation of specific growth-modulating genes and promote oncogenesis in the presence of an appropriate transcriptional coactivator.
GST pull-down assays have confirmed that the WW domain
of RUNX1 interacts directly with YAP65.26 Since all members of
the RUNX family contain a perfectly conserved 10 amino acids
containing the PY motif, RUNX2 was believed to directly interact
with YAP65. In addition, the TAZ coactivator, which is highly
similar to YAP65, interacts with RUNX2.36 Immunoprecipitation
assays verified the interaction between RUNX2 and YAP65 (Fig. 2).
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Published data have shown that Ala substitutions of the first, second, the putative oncogene MCT-1.41 In addition, several reports have
or fourth amino acid (PPPY) in the PY motif abolish binding to the shown that p21CIP1 expression may contribute to tumor progression
WW domain of YAP65.26,37 Mutation of the first proline residue in prostate,48 ovarian,49 cervical,50 breast51 and esophageal52
to alanine (P409A) resulted in the inability of YAP65 to associate carcinomas, and brain tumors53 perhaps by promoting the synthesis
with the mutated RUNX2 as shown by immunoprecipitation assays of genes involved in cell survival.46 Consistent with these obser(Fig. 2) and failure to stimulate growth in soft agar (Fig. 3). vations, YAP65 interaction with RUNX2 relieves p21CIP1 repression
As expected, RUNX2(P409A) retained the ability to bind DNA (Fig. 5), and maintains p21CIP1 protein expression (Fig. 4B), which
and, similar to wild-type RUNX2, RUNX2(P409A) also repressed could mediate cell survival in the context of anchorage independent
the p21CIP1 promoter as shown using transactivation assays growth. Recent reports have shown that p21CIP1 reduces
(Fig. 5). Therefore, the point mutation in RUNX2(P409A) did not the effectiveness of DNA damaging agents in HCT116 colorectal cancer
54
affect RUNX2 DNA binding or transcriptional repression activity. cells by inhibiting DNA damage-induced apoptotic events. These
However, YAP65 could not bind RUNX2(P409A), and YAP65 was observations are consistent with our results showing that HCT116
CIP1, form colonies in soft agar
not able to relieve the repression mediated by the RUNX2(P409A) cells, which express high levels of p21
CIP1 are deficient in colony formation
while
cells
with
low
levels
of
p21
mutant indicating that direct binding of YAP65 to RUNX2 is neces(Fig. 4A). CDK inhibitors may, therefore, contribute to cell transforsary to relieve repression of the p21CIP1 promoter.
RUNX2 contains multiple lysine residues that are the targets mation by reducing cell sensitivity to proapoptotic signals.
In conclusion, we have demonstrated that the RUNX2 transcripof protein acetylation and ubiquitination.38 The E3 ligases, smad
CIP1 and that YAP65
ubiquitination-related factors (Smurfs) interact with the PPxY tion factor is a repressor of the cdk inhibitor p21
CIP1 promoter and protein repression by direct interacalleviates
p21
motif of RUNX2 through their WW domains leading to RUNX2
ubiquitination and degradation by the proteasome pathway.39,40 tion with RUNX2. YAP65 and RUNX2 expression reduced cell:
Since YAP65 interacts with the same PPxY motif on RUNX2, cell contact inhibition and synergistically enhanced anchorage-indeAlthough the association
YAP65 binding could block ubiquitination and stabilize RUNX2 pendent growth of NIH3T3 fibroblasts.
CIP1 promoter may contribute
of
RUNX2
and
YAP65
on
the
p21
levels, thus increasing cell transformation. Further studies to address
whether any of these mechanisms are operative in RUNX2-mediated to cellular transformation, it is possible that RUNX2-YAP65 may
cell transformation are being pursued. Experiments in rat osteosar- control the expression of other genes that regulate cellular transcoma (ROS 17/2.8) cells showed that YAP65 was able to suppress the formation. Therefore, future studies using this model of tumor
ability of RUNX2 to activate the osteocalcin gene promoter, but had progression will include a comparative analysis of gene expression
no effect on p21CIP1 promoter activity.37 Since we have found that patterns from parental cells and RUNX2-YAP65 expressing cells to
YAP65 inhibits the repression of the p21CIP1 promoter in NIH3T3 further elucidate the mechanisms regulating cell transformation and
cells, it is possible that p21CIP1 promoter regulation by RUNX2 and to identify inhibitory therapeutic agents.
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